Short-term benefits for immunotherapy in allergic asthma

Short-term benefits for immunotherapy in allergic asthma

(HealthDay)—Administration of allergen immunotherapy (AIT) in patients with allergic asthma leads to lower short-term symptom and medication scores, according to a review published online May 19 in Allergy.

Sangeeta Dhami, M.B.B.S., from Evidence-Based Health Care in Edinburgh, U.K., and colleagues performed a systematic review to examine evidence on the effectiveness, cost-effectiveness, and safety of AIT. Data were reviewed from 98 studies.

The researchers observed a reduction in short-term symptom and medication scores, with evidence found for publication bias. No reduction was seen in short-term combined medication and symptom scores; a beneficial long-term effect was seen in one study. Subcutaneous immunotherapy correlated with improved quality of life and reduction in allergen-specific airway hyperreactivity (AHR); this was not seen for (SLIT). No consistent effects were seen on control, exacerbations, lung function, or non-specific AHR. There was a modest increase in the risk of adverse events with AIT. Evidence on cost-effectiveness was mainly available for SLIT, which was likely to be cost-effective.

"AIT can achieve substantial reductions in short-term symptom and scores in ," the authors write. "More data are needed in relation to secondary outcomes, longer-term effectiveness, and cost-effectiveness."

Several authors disclosed financial ties to the biopharmaceutical industry.


Explore further

Shorter course of immunotherapy does not improve symptoms of allergic rhinitis long-term

More information: Abstract
Full Text
Journal information: Allergy

Copyright © 2017 HealthDay. All rights reserved.

Citation: Short-term benefits for immunotherapy in allergic asthma (2017, June 4) retrieved 1 October 2020 from https://medicalxpress.com/news/2017-06-short-term-benefits-immunotherapy-allergic-asthma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
62 shares

Feedback to editors

User comments